Bio Path: Jumps on third U.S. patent for drug manufacturing tech

Bio Path Holdings

10/02/2021 13:09

** Biotech firm's  BPTH.O  shares surge ~50% to $7.88
premarket - among top pct gainers across U.S. exchanges
    ** U.S. Patent and Trademark Office grants third patent to
company's DNAbilize platform technology  urn:newsml:reuters.com:*:nGNX1c9gs7
    ** DNAbilize platform technology is Bio Path's patented
method for producing and delivering its DNA therapeutics
including lead candidate, prexigebersen, to treat different
types of cancer in combination with front-line therapies 
    ** Prexigebersen is currently in a mid-stage trial in
combination with chemotherapy drug, decitabine, as a treatment
for acute myeloid leukemia
    ** Stock has gained 48.5% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))